Approval · Notice of Compliance 8568 · 2007
PLAVIX: Notice of Compliance 8568
Issued February 2, 2007
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 8568
- Date
- February 2, 2007
- Company
- Sanofi-Aventis Canada Inc.Toronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Priority
- Reason
- New indication: for patients with st-segment elevation acute myocardial infarction, plavix has been shown to reduce the rate of an endpoint of all-cause mortality and the rate of a combined endpoint of death, re-infarction or stroke and other revisions to the product monograph
- Therapeutic class
- Platelet aggregation inhibitor
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| PLAVIX | Not yet assigned | — |
Medicinal ingredients
- CLOPIDOGREL BISULFATE 75 MG per TAB